Lonafarnib - 95%, high purity , Protein farnesyltransferase inhibitor, CAS No.193275-84-2, Protein farnesyltransferase inhibitor

Item Number
L125407
Grouped product items
SKUSizeAvailabilityPrice Qty
L125407-1mg
1mg
In stock
$28.90
L125407-5mg
5mg
In stock
$117.90
L125407-10mg
10mg
In stock
$187.90
L125407-25mg
25mg
In stock
$375.90
L125407-50mg
50mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$593.90
L125407-100mg
100mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,069.90

Effective faniki protein transferase (FPTASE) inhibitors

Basic Description

SynonymsLonafarnib | 193275-84-2 | Sarasar | Sch66336 | Sch 66336 | Sch-66336 | Zokinvy | lonafarnibum | UNII-IOW153004F | IOW153004F | CHEMBL298734 | (+)-4-(2-(4-(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-piperidin-1-yl))-2-oxoethyl)-piperid
Specifications & PurityMoligand™, ≥95%
Biochemical and Physiological MechanismsEffective Farnesyltransferase inhibitor (IC50 = 1.9 nM). Inhibition of Ras by Farnesitization. When used with CYTOTOXIC PGP substrate, PGP transport was also inhibited (IC50 & Lt; 3 μm) and its potency and anti-cancer activity were increased. Inhibit the
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionProtein farnesyltransferase inhibitor

Product Properties

ALogP4.8

Associated Targets(Human)

KRAS Tclin GTPase KRas (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
HRAS Tchem GTPase HRas (2 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
NRAS Tchem GTPase NRas (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
HRAS Tchem Transforming protein p21/H-Ras-1 (138 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYP3A4 Tclin Cytochrome P450 3A4 (53859 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Caco-2 (12174 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MCF7 (126967 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HCT-116 (91556 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FNTA Tclin Protein farnesyltransferase (3470 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FNTA Tclin Geranylgeranyl transferase type I (851 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Abcb1b P-glycoprotein 1 (174 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Hdac6 Histone deacetylase 6 (222 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Plasmodium falciparum (966862 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
COS-1 (266 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NIH3T3 (5395 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Cynomolgus monkey (4946 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
rep Replicase polyprotein 1ab (378 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Pggt1b geranylgeranyltransferase type-I (82 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Protein farnesyltransferase (PFT) (124 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SARS-CoV-2 (38078 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Names and Identifiers

IUPAC Name 4-[2-[4-[(2R)-6,15-dibromo-13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl]piperidin-1-yl]-2-oxoethyl]piperidine-1-carboxamide
INCHI InChI=1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1
InChi Key DHMTURDWPRKSOA-RUZDIDTESA-N
Canonical SMILES C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N
Isomeric SMILES C1CN(CCC1CC(=O)N2CCC(CC2)[C@@H]3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N
PubChem CID 148195
Molecular Weight 638.82

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

6 results found

Lot NumberCertificate TypeDateItem
B2209334Certificate of AnalysisNov 15, 2023 L125407
B2209336Certificate of AnalysisNov 15, 2023 L125407
B2209338Certificate of AnalysisNov 15, 2023 L125407
B2209345Certificate of AnalysisNov 15, 2023 L125407
B2209434Certificate of AnalysisNov 15, 2023 L125407
B2209415Certificate of AnalysisNov 23, 2021 L125407

Chemical and Physical Properties

SolubilitySolvent:DMSO, Max Conc. mg/mL: 6.39, Max Conc. mM: 10 with gentle warming
Melt Point(°C)150-152°C

Safety and Hazards(GHS)

Pictogram(s) GHS08
Signal Warning
Hazard Statements

H373:Causes damage to organs through prolonged or repeated exposure

H361:Suspected of damaging fertility or the unborn child

Precautionary Statements

P280:Wear protective gloves/protective clothing/eye protection/face protection.

P405:Store locked up.

P501:Dispose of contents/container to ...

P260:Do not breathe dust/fume/gas/mist/vapors/spray.

P203:Obtain, read and follow all safety instructions before use.

P318:if exposed or concerned, get medical advice.

P319:Get medical help if you feel unwell.

Related Documents

References

1. Taveras AG, Kirschmeier P, Baum CM.  (2003)  Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations..  Curr Top Med Chem,  (10): (1103-14).  [PMID:12769711]
2. Gordon LB, Kleinman ME, Miller DT, Neuberg DS, Giobbie-Hurder A, Gerhard-Herman M, Smoot LB, Gordon CM, Cleveland R, Snyder BD et al..  (2012)  Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome..  Proc Natl Acad Sci USA,  109  (41): (16666-71).  [PMID:23012407]
3. Young SG, Yang SH, Davies BS, Jung HJ, Fong LG.  (2013)  Targeting protein prenylation in progeria..  Sci Transl Med,  (171): (171ps3).  [PMID:23390246]
4. Moorthy NS, Sousa SF, Ramos MJ, Fernandes PA.  (2013)  Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis..  Curr Med Chem,  20  (38): (4888-923).  [PMID:24059235]
5. Gordon LB, Shappell H, Massaro J, D'Agostino Sr RB, Brazier J, Campbell SE, Kleinman ME, Kieran MW.  (2018)  Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome..  JAMA,  319  (16): (1687-1695).  [PMID:29710166]
6. Downward J.  (2003)  Targeting RAS signalling pathways in cancer therapy..  Nat Rev Cancer,  (1): (11-22).  [PMID:12509763]

Solution Calculators